Though PACAP has demonstrated neuroprotective effects preclinically, its clinical use in stroke and neurodegenerative disorders is limited on account of its metabolic instability, poor bioavailability, sparse distribution, and quick clearance from the bloodstream akin to other natural peptides [114]. This evidence concerns the gene ADCYAP1 and stroke disorder.